Effectiveness of Bisphosphonates on Nonvertebral and Hip Fractures in the First Year of Therapy: the Risedronate and Alendronate (REAL) Cohort Study

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2006 Nov 16

PMID 17106785

Citations 61

Authors

S L Silverman

N B Watts

P D Delmas

J L Lange

R Lindsay

Affiliations

Soon will be listed here.

Abstract

Introduction: Randomized clinical trials have shown that risedronate and alendronate reduce fractures among women with osteoporosis. The aim of this observational study was to observe, in clinical practice, the incidence of hip and nonvertebral fractures among women in the year following initiation of once-a-week dosing of either risedronate or alendronate.

Methods: Using records of health service utilization from July 2002 through September 2004, we created two cohorts: women (ages 65 and over) receiving risedronate (n = 12,215) or alendronate (n = 21,615). Cox proportional hazard modeling was used to compare the annual incidence of nonvertebral fractures and of hip fractures between cohorts, adjusting for potential differences in risk factors for fractures.

Results: There were 507 nonvertebral fractures and 109 hip fractures. Through one year of therapy, the incidence of nonvertebral fractures in the risedronate cohort (2.0%) was 18% lower (95% CI 2% - 32%) than in the alendronate cohort (2.3%). The incidence of hip fractures in the risedronate cohort (0.4%) was 43% lower (95% CI 13% - 63%) than in the alendronate cohort (0.6%). These results were consistent across a number of sensitivity analyses.

Conclusion: Patients receiving risedronate have lower rates of hip and nonvertebral fractures during their first year of therapy than patients receiving alendronate.

Citing Articles

Prevention and treatment of osteoporosis in women.

Stevenson J Post Reprod Health. 2022; 29(1):11-14.

PMID: 36357006 PMC: 10009319. DOI: 10.1177/20533691221139902.

Effects of risedronate, alendronate, and minodronate alone or in combination with eldecalcitol on bone mineral density, quality, and strength in ovariectomized rats.

Yano T, Ito T, Kanehira Y, Yamada M, Kimura-Suda H, Wagatsuma H Bone Rep. 2021; 14:101061.

PMID: 33898659 PMC: 8055548. DOI: 10.1016/j.bonr.2021.101061.

Anorexia Nervosa and Osteoporosis: Pathophysiology and Treatment.

Steinman J, Shibli-Rahhal A J Bone Metab. 2019; 26(3):133-143.

PMID: 31555610 PMC: 6746661. DOI: 10.11005/jbm.2019.26.3.133.

Advances and Unmet Needs in the Therapeutics of Bone Fragility.

Ramchand S, Seeman E Front Endocrinol (Lausanne). 2018; 9:505.

PMID: 30237785 PMC: 6135909. DOI: 10.3389/fendo.2018.00505.

Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.

Karlsson L, Mesterton J, Tepie M, Intorcia M, Overbeek J, Strom O Arch Osteoporos. 2017; 12(1):81.

PMID: 28936581 PMC: 5608859. DOI: 10.1007/s11657-017-0375-7.

References

Black N . Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996; 312(7040):1215-8. PMC: 2350940. DOI: 10.1136/bmj.312.7040.1215. View

Liberman U, Weiss S, Broll J, Minne H, Quan H, Bell N . Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995; 333(22):1437-43. DOI: 10.1056/NEJM199511303332201. View

Harris S, Watts N, Genant H, McKeever C, Hangartner T, Keller M . Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282(14):1344-52. DOI: 10.1001/jama.282.14.1344. View

Grimes D, Schulz K . Bias and causal associations in observational research. Lancet. 2002; 359(9302):248-52. DOI: 10.1016/S0140-6736(02)07451-2. View

Hochberg M, Greenspan S, Wasnich R, Miller P, Thompson D, Ross P . Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002; 87(4):1586-92. DOI: 10.1210/jcem.87.4.8415. View

Melton 3rd L, Crowson C, OFallon W . Fracture incidence in Olmsted County, Minnesota: comparison of urban with rural rates and changes in urban rates over time. Osteoporos Int. 1999; 9(1):29-37. DOI: 10.1007/s001980050113. View

Watts N, Geusens P, Barton I, Felsenberg D . Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005; 20(12):2097-104. DOI: 10.1359/JBMR.050814. View

Ray W, Griffin M, Fought R, Adams M . Identification of fractures from computerized Medicare files. J Clin Epidemiol. 1992; 45(7):703-14. DOI: 10.1016/0895-4356(92)90047-q. View

Cummings S, Black D, Thompson D, Applegate W, Barrett-Connor E, Musliner T . Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1999; 280(24):2077-82. DOI: 10.1001/jama.280.24.2077. View

10.

Peng R, Dominici F, Zeger S . Reproducible epidemiologic research. Am J Epidemiol. 2006; 163(9):783-9. DOI: 10.1093/aje/kwj093. View

11.

Stafford R, Drieling R, Hersh A . National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med. 2004; 164(14):1525-30. DOI: 10.1001/archinte.164.14.1525. View

12.

Zhou Z, Rahme E, Abrahamowicz M, Tu J, Eisenberg M, Humphries K . Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ. 2005; 172(9):1187-94. PMC: 557070. DOI: 10.1503/cmaj.1041403. View

13.

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

14.

McClung M, Geusens P, Miller P, Zippel H, Bensen W, Roux C . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344(5):333-40. DOI: 10.1056/NEJM200102013440503. View

15.

Black D, Thompson D, Bauer D, Ensrud K, Musliner T, Hochberg M . Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85(11):4118-24. DOI: 10.1210/jcem.85.11.6953. View

16.

Nancollas G, Tang R, Phipps R, Henneman Z, Gulde S, Wu W . Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2005; 38(5):617-27. DOI: 10.1016/j.bone.2005.05.003. View

17.

Klungel O, Martens E, Psaty B, Grobbee D, Sullivan S, Stricker B . Methods to assess intended effects of drug treatment in observational studies are reviewed. J Clin Epidemiol. 2004; 57(12):1223-31. DOI: 10.1016/j.jclinepi.2004.03.011. View

18.

Sikka R, Xia F, Aubert R . Estimating medication persistency using administrative claims data. Am J Manag Care. 2005; 11(7):449-57. View

19.

Psaty B, Heckbert S, Koepsell T, Siscovick D, Raghunathan T, Weiss N . The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995; 274(8):620-5. View

20.

Harrington J, Ste-Marie L, Brandi M, Civitelli R, Fardellone P, Grauer A . Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2003; 74(2):129-35. DOI: 10.1007/s00223-003-0042-4. View